Breda, The Netherlands / Ghent, Belgium - arGEN-X N.V. (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment o [...]
Breda, The Netherlands / Ghent, Belgium - arGEN-X N.V. (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment o [...]
Swiss company’s innovative technology enables the automated management of excess fluid around the lungs for the first time ever.
Zurich, SWITZERLAND – 05. November 2014
Sequana Medical AG, a [...]
Amsterdam, the Netherlands, 4 November 2014. LSP (Life Sciences Partners), a leading European investor in health care, today announces that its portfolio company Nexstim was successfully listed on Nasdaq First North F [...]
Agreement enhances existing relationship between Celladon and Lonza for the manufacture of MYDICAR®
Lonza to initiate design of a new commercial viral therapeutics facility in Portsmouth, NH (USA) [...]
Breda, The Netherlands / Ghent, Belgium - arGEN-X N.V. (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment o [...]
Our portfolio company Probiodrug AG, based in Halle/Saale, Germany, raised € 22.5 million in an initial public offering (IPO) through a listing in Euronext Amsterdam. LSP has co-led the Series B financing o [...]
AG014 Safe and Well Tolerated, Successful Localized GI Delivery of Drug With
No Systemic Exposure
Ghent, Belgium, October 15, 2014 -- ActoGeniX, a clinical stage biopharmaceutical company, today announced [...]
Based on evidence of activity, T-cell lymphomas selected as indication for initial efficacy studies
October 15, 2014 - Breda, The Netherlands / Ghent, Belgium – arGEN-X N.V. (Euronext Brussels: ARGX), a c [...]
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY,IN THE USA, AUSTRALIA, CANADA, HONG KONG, JAPAN OR SOUTH AFRICA OR ANY OTHER JURSIDICTION WHERE SUCH PUBLICATION OR DISTRIBUTION [...]
Breda, The Netherlands / Ghent, Belgium - arGEN-X N.V. (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment o [...]
Breda, The Netherlands / Ghent, Belgium - arGEN-X N.V. (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment o [...]
Swiss company’s innovative technology enables the automated management of excess fluid around the lungs for the first time ever.
Zurich, SWITZERLAND – 05. November 2014
Sequana Medical AG, a [...]
Amsterdam, the Netherlands, 4 November 2014. LSP (Life Sciences Partners), a leading European investor in health care, today announces that its portfolio company Nexstim was successfully listed on Nasdaq First North F [...]
Agreement enhances existing relationship between Celladon and Lonza for the manufacture of MYDICAR®
Lonza to initiate design of a new commercial viral therapeutics facility in Portsmouth, NH (USA) [...]
Breda, The Netherlands / Ghent, Belgium - arGEN-X N.V. (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment o [...]
Our portfolio company Probiodrug AG, based in Halle/Saale, Germany, raised € 22.5 million in an initial public offering (IPO) through a listing in Euronext Amsterdam. LSP has co-led the Series B financing o [...]
AG014 Safe and Well Tolerated, Successful Localized GI Delivery of Drug With
No Systemic Exposure
Ghent, Belgium, October 15, 2014 -- ActoGeniX, a clinical stage biopharmaceutical company, today announced [...]
Based on evidence of activity, T-cell lymphomas selected as indication for initial efficacy studies
October 15, 2014 - Breda, The Netherlands / Ghent, Belgium – arGEN-X N.V. (Euronext Brussels: ARGX), a c [...]
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY,IN THE USA, AUSTRALIA, CANADA, HONG KONG, JAPAN OR SOUTH AFRICA OR ANY OTHER JURSIDICTION WHERE SUCH PUBLICATION OR DISTRIBUTION [...]
Follow us
